MTI

Minerals Technologies Reports Record First Quarter 2024 Earnings Per Share of $1.44, or $1.49 Excluding Special Items

Retrieved on: 
Thursday, April 25, 2024
Consumer, MTX, Biophysical environment, Growth, Household, MTI, Personal care, Music

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today reported diluted earnings per share of $1.49 for the first quarter ended March 31, 2024, excluding special items. Reported diluted earnings per share were $1.44.

Key Points: 
  • Record Operating Income of $75 Million, or $77 Million Excluding Special Items, a 23% Increase over Prior Year
    Strong Operating Margin of 14.1%, or 14.5% Excluding Special Items, a 290 bps Increase over Prior Year
    NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today reported diluted earnings per share of $1.49 for the first quarter ended March 31, 2024, excluding special items.
  • Operating income excluding special items was $77 million, a record for MTI, and represented 14.5 percent of sales.
  • Growth in higher margin products and a strong operating performance across the company led to record operating income for MTI.
  • Minerals Technologies will host a conference call tomorrow, April 26, 2024, at 11 a.m. Eastern Time.

Midwest Technical Institute announces 2024 High School Welding Competition winners

Retrieved on: 
Wednesday, April 24, 2024
Welding, Student, Midwest Technical Institute, Central High School, MTI, Muscatine High School, Institute of technology, Secondary school

East Peoria, Ill., April 24, 2024 (GLOBE NEWSWIRE) -- Midwest Technical Institute (MTI) held the 2024 Illinois High School Welding Competition at their East Peoria campus on Saturday, April 20.

Key Points: 
  • East Peoria, Ill., April 24, 2024 (GLOBE NEWSWIRE) -- Midwest Technical Institute (MTI) held the 2024 Illinois High School Welding Competition at their East Peoria campus on Saturday, April 20.
  • “The High School Welding Competition was a resounding success, with 28 high schools in attendance and $36,000 in MTI scholarships going to seniors from various local high schools,” said Cole Huff, MTI East Peoria campus president.
  • The second-prize winner, Dylan Wood from Midwest Central High School, received a $2,500 scholarship.
  • “The annual welding competition helps spark a love of welding and sharpens students’ skills,” said Huff.

Makana™ Issued Patent in South Korea for Its Genetically-Modified TKO Pig for Use in Xenotransplantation

Retrieved on: 
Wednesday, May 1, 2024
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University, Genetics, National Kidney Foundation, Food, Kidney failure, Makana, Immunosuppression, Doctor of Philosophy, Jackson Memorial Hospital, Medicine, FACS, Organ transplantation, Patent, Massachusetts General Hospital, TKO, Patient, MTI, Kidney, Maryland School, Immune system, Clinical trial, Therapy, Quality of life, Pelvic floor dysfunction, Pharmaceutical industry

Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.

Key Points: 
  • Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.
  • The South Korean patent was granted on Makana’s Triple Knockout pig, or “TKO,” which is a combination of three xenoantigen gene knockouts in the pig that effectively camouflage the cross-species grafts from the human recipient’s immune system.
  • Platt added, “The Triple Knockout Pig has fundamentally changed the field and has moved xenotransplantation closer to becoming a clinically available reality.
  • “The TKO pig is widely seen as the preferred genetic profile that will enter clinical trials,” Platt said.

Minerals Technologies Announces Election of Kristina M. Johnson to Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Master of Science, Electrical engineering, Ohio State University, I Squared Capital, State university system, Education, Duke University, University, Electricity, MTX, Senior, MTI, Mineral, Cisco, State, Stanford University, National academy, Johns Hopkins University, Computer, Government, Management

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.
  • “We are excited to welcome Kristina Johnson to our Board,” said Douglas T. Dietrich, Chairman and Chief Executive Officer.
  • She currently serves on the boards of DuPont and Cisco Systems, Inc., and previously served on the Minerals Technologies Inc. Board from 2000 to 2009.
  • Dr. Johnson will begin her service on the MTI Board of Directors on May 13, 2024.

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
Thursday, March 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

AgEagle Aerial Systems Appoints Seasoned Defense Industry Executive William Irby as President

Retrieved on: 
Thursday, February 15, 2024
Acquisition, Weapon, Atmosphere, Technical management, ISR, Growth, Technical, UAS, Government, United States Naval Academy, Interim, Engineering, Grumman, AUVSI, Johns Hopkins University, MTI, Robotics, Software, Northrop Grumman, Management

AgEagle’s Chairman and Interim CEO, Grant Begley, commented, “Bill is a timely and exciting addition to AgEagle’s leadership team. His significant defense industry experience -- particularly in scaling unmanned technology, product development, and business operations -- will be transformative for AgEagle as we enter our next stage of growth. We believe Bill’s deep domain UAS professional successes and industry foresight will contribute as we continue to expand our market footprint and focus on building sustainable shareholder value.”

Key Points: 
  • WICHITA, Kan., Feb. 15, 2024 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of best-in-class full stack unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, today announces the appointment of William ”Bill” Irby as President, effective February 12, 2024.
  • AgEagle’s Chairman and Interim CEO, Grant Begley, commented, “Bill is a timely and exciting addition to AgEagle’s leadership team.
  • His significant defense industry experience -- particularly in scaling unmanned technology, product development, and business operations -- will be transformative for AgEagle as we enter our next stage of growth.
  • I am eager to leverage my expertise in scaling operations within the global defense and security industry to help drive long-term value for all our stakeholders.”

Meilleur Technologies Inc. Announces Execution of Manufacturing Agreement with PharmaLogic for Production of the Next-Generation Amyloid PET Imaging Biomarker, NAV4694

Retrieved on: 
Wednesday, December 20, 2023
Health, Neurology, Managed Care, Radiology, Pharmaceutical, Biotechnology, Disease, Positron emission tomography, PET, Brain, Alzheimer's disease, Neurodegenerative disease, Acceleration, MTI, Pharmaceutical industry

Meilleur Technologies Inc. (MTI) today announced it has signed an agreement with PharmaLogic Holdings Corporation (“PharmaLogic”) granting PharmaLogic the rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography (PET) imaging studies to assess the status of amyloid plaque in the brain.

Key Points: 
  • Meilleur Technologies Inc. (MTI) today announced it has signed an agreement with PharmaLogic Holdings Corporation (“PharmaLogic”) granting PharmaLogic the rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography (PET) imaging studies to assess the status of amyloid plaque in the brain.
  • Amyloid plaques are one of the pathological hallmarks of several neurodegenerative diseases, including Alzheimer’s Disease (AD).
  • Under the terms of its agreement, PharmaLogic will manufacture [F18]NAV4694 for use in clinical trials at select United States-based radiopharmacies.
  • “We are delighted that the NAV4694 clinical and research program will be supported by Pharmalogic's extensive PET manufacturing and dispensing expertise,” said Rick Hiatt, President and CEO of Meilleur Technologies, Inc. “Meilleur is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative disease.

MedTech Innovator Crowns MicroTransponder and Mirai Medical Among its Top Innovators of 2023

Retrieved on: 
Friday, November 17, 2023
Research, Medical Devices, Surgery, Hospitals, FDA, Health Technology, Biotechnology, Health, Science, Oncology, Yee, Corporation, Running, Patient, Stroke, MTI, Medtech, Q&A, Conference, Standard of care, Johnson & Johnson, Cancer, Prize, Pharmaceutical industry, Grand

MedTech Innovator (MTI), the world’s largest accelerator of medical devices, today announced that MicroTransponder won the inaugural 2023 Mid-Stage Grand Prize competition, and Mirai Medical won the 2023 Value Award during the MedTech Strategist Innovation Summit in San Francisco .

Key Points: 
  • MedTech Innovator (MTI), the world’s largest accelerator of medical devices, today announced that MicroTransponder won the inaugural 2023 Mid-Stage Grand Prize competition, and Mirai Medical won the 2023 Value Award during the MedTech Strategist Innovation Summit in San Francisco .
  • The 2023 cohort was selected from over 1,100 applicants, receiving mentorship, resources, access to industry stakeholders, industry visibility, and over $800,000 in awards.
  • StrokeDX was crowned the 2023 Early Stage Grand Prize winner after the audience vote on October 10, 2023, at AdvaMed’s The MedTech Conference.
  • MicroTransponder received the largest MedTech Strategist live audience vote on November 15, winning the $200,000 Grand Prize for its transformative stroke treatment technology.

Celgard and Senior Settle Their Global Litigations

Retrieved on: 
Thursday, November 16, 2023
Senior, MTI, Intellectual property, District court, LP, Polypore

CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.

Key Points: 
  • CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.
  • In the public California District Court and UK litigation filings:
    Celgard voluntarily dismissed all claims against the Senior defendants asserted in its Sixth Amended Complaint in the California District Court.
  • Also, the Senior defendants voluntarily dismissed all counterclaims against Celgard and Polypore.
  • Earlier, Celgard announced the successful outcome of the Targray ( See Release ), MTI ( See Release ) and Farasis cases ( See Release ).

Celgard and Senior Settle Their Global Litigations

Retrieved on: 
Thursday, November 16, 2023
Senior, MTI, Intellectual property, District court, LP, Polypore

CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.

Key Points: 
  • CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.
  • In the public California District Court and UK litigation filings:
    Celgard voluntarily dismissed all claims against the Senior defendants asserted in its Sixth Amended Complaint in the California District Court.
  • Also, the Senior defendants voluntarily dismissed all counterclaims against Celgard and Polypore.
  • Earlier, Celgard announced the successful outcome of the Targray ( See Release ), MTI ( See Release ) and Farasis cases ( See Release ).